Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with ...
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...